Compare ASYS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | LCTX |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.5M | 301.7M |
| IPO Year | 2006 | 1996 |
| Metric | ASYS | LCTX |
|---|---|---|
| Price | $15.83 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 385.4K | ★ 949.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $79,364,000.00 | $14,556,000.00 |
| Revenue This Year | $2.82 | $109.40 |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $176.56 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $4.30 | $0.95 |
| 52 Week High | $25.71 | $2.09 |
| Indicator | ASYS | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 28.98 |
| Support Level | $10.84 | N/A |
| Resistance Level | $18.00 | $1.32 |
| Average True Range (ATR) | 1.18 | 0.06 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 2.88 | 2.81 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.